XOMA Corporation XOMA Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Income Not From Contract With Customer Cost Recovery Method by Product | ||||||
| Tovorafenib | $2.77M-40.1% | $4.62M+149% | $1.86M+8.3% | $1.72M-69.0% | $5.53M+328% | |
| Revenue by Geography | ||||||
| CH | $6.7M+18.3% | $5.66M-15.8% | $6.72M+16.8% | $5.76M-1.0% | $5.82M+20.8% | |
| US | $5.62M-19.7% | $7M+166% | $2.63M-64.3% | $7.37M+20.9% | $6.1M+168% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does XOMA Corporation break its business down?
- XOMA Corporation (XOMA) reports income not from contract with customer cost recovery method by product across 2 parts — Dsuvia and Tovorafenib. Each is extracted from the segment footnotes and tracked over time.
- Where does XOMA Corporation's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in XOMA Corporation's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
